GSK said Thursday it plans to divest its remaining 4.2% stake in the consumer health spinout, its fourth and final round of ...

A Senate health committee report published Wednesday forecasts spending on prescription drugs may hit $1 trillion a year in ...

Bayer on Thursday provided additional data on late-stage studies of its rival drug to Astellas’ Veozah, which met all primary ...

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...

Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma ...

Belgian biotech Galapagos is teaming with Blood Centers of America to help deploy its decentralized CAR-T therapy ...

Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational ...

Bolstered by promising response data from its Phase II study, Amgen announced Thursday it got the FDA’s green light for its first-in-class bi-specific T-cell engager Imdelltra for extensive-stage ...

Amylyx’s recent decision to withdraw its ALS drug Relyvrio from the market highlights an important business decision for ...

In Tuesday’s first-quarter 2024 financial results, Bayer reported a slight drop in sales amid its sweeping companywide ...

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, ...

With Monday’s agreement, AbbVie joins the industry’s growing interest in psychedelic therapies and looks to leverage ...